Key Terms at a Glance

1. What is NSI-189, fundamentally?

NSI-189 (now also known by the formal, non-trademarked name amdiglurax, and more recently the code ALTO-100) is a small, synthetic molecule first developed by a Maryland-based biotechnology company called Neuralstem. It belongs to a category that researchers describe as a “hippocampal neurogenesis stimulant” or, more simply, a “neurogenic” compound.

That single word — neurogenic — is the key to everything, because NSI-189 was built around an idea that differs sharply from how almost all previous psychiatric drugs work.

A different philosophy for treating the brain

Most classical antidepressants adjust the levels of chemical messengers (monoamines like serotonin) that neurons use to signal each other. It’s a bit like changing the volume of a conversation the brain is already having.

NSI-189 was based on the hypothesis that, at least for some conditions, the problem isn’t the volume of signaling but the physical hardware itself — the actual cells and connections. The goal was not to tweak chemistry but to encourage the brain to grow new cells and rewire damaged circuits. If successful, this would represent a fundamentally different — some would say more “repair-oriented” — approach to treating brain disorders.

The premise rests on real observations, not conjecture:

• Imaging and autopsy studies have repeatedly found that people with major depression often have a slightly smaller hippocampus, the brain’s memory-and-mood hub.
• The shrinkage tends to track with severity and recurrence: more and longer episodes are associated with greater volume loss.
• Classic antidepressant treatment can partially reverse this atrophy, and some researchers believe this reversal is central to recovery.

Put those findings together and a natural question emerges: if we could directly stimulate hippocampal growth, might we treat depression more durably — and perhaps help other conditions involving brain damage or degeneration? That’s the scientific logic behind NSI-189, and it’s a legitimate, testable hypothesis.

2. How it was discovered: a large-scale biological “fishing expedition”

The discovery story matters because it explains both the promise and one of NSI-189’s most important limitations.

Neuralstem specialized in growing human neural stem cells — the immature cells that can mature into neurons. They reasoned that if they could grow these cells in a dish and watch them, they could search for chemicals that made them multiply and mature faster. So they screened a library of more than 10,000 compounds, one by one, against these cells. NSI-189 was among the standout “hits.”

That is precisely NSI-189’s situation. The outcome (more neurons growing) was observed and is real. The mechanism remains only partially understood — a theme we’ll keep returning to.

What the early lab work showed

• In human neural stem cells in culture, NSI-189 stimulated the cells to proliferate and become neurons.
• In healthy young mice, NSI-189 increased new-neuron production in the hippocampus and enlarged the hippocampus by as much as ~66% at higher doses in some experiments. (Notably, the effect was “bell-shaped” — the highest dose tested was actually less effective, a pattern seen with many drugs.)
• The effects appeared restricted to two known “neurogenic zones” of the adult brain — the hippocampus and a nearby region called the subventricular zone — with no obvious effect elsewhere.

That last point is worth dwelling on, because it’s actually reassuring. A molecule that made cells grow everywhere would be alarming. NSI-189’s apparent specificity to the brain’s natural stem-cell niches made it look more like a careful, targeted signal than a blunt growth factor.

3. How does NSI-189 work? (An honest partial answer)

Here’s where intellectual honesty requires a direct statement: The exact molecular target of NSI-189 is still not definitively established. This is unusual for a modern drug and is itself an important fact.

Most medicines work by “docking” onto a specific receptor or enzyme — a key fitting a lock. NSI-189 does not appear to work that way, or at least not through any common lock we know to look for. Researchers screened it against a large panel of neurochemical targets:

• It doesn’t bind serotonin, norepinephrine, or dopamine systems.
• It doesn’t bind other amino-acid targets like the NMDA or AMPA receptors.
• Screens against ~900 kinases (a class of enzymes) came back negative — and so did screens against dozens of neurotransmitter receptors, ion channels, and enzymes.

So what does it do? The best-supported picture involves growth-factor signaling:

• NSI-189 appears to boost the brain’s own production and signaling of neurotrophins — most prominently BDNF (brain-derived neurotrophic factor), but also related factors like GDNF, VEGF, and SCF.
• Preclinical work found NSI-189 activates the TrkB/Akt pathway — a well-known signaling route that BDNF uses — and that blocking BDNF or its cousin SCF partly cancels NSI-189’s effects in lab models.

There’s also a newer lead. A 2022 patent disclosed evidence that NSI-189 acts as an exceptionally potent activator (agonist) of a nuclear receptor called TLX/NR2E1, which is described as a “master regulator” of hippocampal neurogenesis. If broadly confirmed, that would give the field a long-sought molecular “lock” for the key. But this remains a patent disclosure, not yet established by independent, peer-reviewed human evidence.

The honest bottom line: NSI-189 seems to tilt the brain toward a “grow and repair” state, chiefly by boosting the brain’s own growth-factor machinery. The precise first molecular handshake — the exact lock it turns — is still an open question. And an unknown mechanism carries consequences, because it’s harder to predict a drug’s full range of effects (and side effects) when you’re not entirely sure what it’s doing.

4. The clinical evidence: a methodical look at the human trials

Phase 1b (published 2016): small, safe, and cautiously interesting

• Design: 24 adults with major depressive disorder, given NSI-189 at 40 mg once, twice, or three times daily — or placebo — for 28 days, in an inpatient setting.
• Primary purpose: safety and dosing, not proof of effectiveness.
• Findings: The drug was relatively well tolerated at all doses, with no serious adverse events. On exploratory symptom questionnaires (the SDQ and CPFQ, among others), people on NSI-189 improved more than those on placebo, with some benefits persisting after treatment stopped.
• Brain scans: Did not show a clear increase in hippocampal or amygdala volume, despite the dramatic volume increases seen in mice. There was a modest, non-significant numerical trend in the left hippocampus.
• Interpretation: A whisper, not a shout. The authors themselves framed the mood findings as exploratory. Small trials of this size frequently produce encouraging signals that don’t survive larger testing.

Phase 2 (announced 2017, published 2020): the decisive test — and a miss on the main goal

This was the study that mattered. About 220 outpatients with major depressive disorder were randomized to 40 mg/day, 80 mg/day, or placebo for 12 weeks.

The headline result: On the primary outcome — the clinician-rated Montgomery–Åsberg Depression Rating Scale (MADRS) — neither dose beat dramatically placebo. The differences were small and not statistically significant (40 mg: −1.8 points, p = 0.22; 80 mg: −1.4 points, p = 0.34).

But the trial was not a clean washout. On a cluster of secondary measures — especially at the 40 mg dose — there were:

• Patient-rated depression symptom questionnaires (SDQ, CPFQ, and QIDS-SR in part) showed statistically significant improvements over placebo. Specific items that improved included low mood, anxiety, crying, decision-making, ability to work, optimism, and outlook on life.
• Objective computerized cognitive tests (the CogScreen battery, though notably not the Cogstate battery) showed advantages in attention, executive function (mental flexibility), and — most strikingly — delayed recall on a memory test. A later analysis suggested the largest effects were on tests of memory and on how people responded to negative feedback.

It’s notable these cognitive signals replicated earlier signs from the Phase 1b trial, which lends them some credibility beyond pure noise.

A later post-hoc analysis (2020) added more nuance: when researchers split the Phase 2 participants by depression severity, NSI-189’s benefits — both mood and cognitive — appeared concentrated in people with moderate depression (MADRS < 30), rather than severe depression. In that moderate subgroup, the 80 mg dose even beat placebo on a six-item subset of the MADRS.

5. “Phosphate powder” — decoding the name

The chemistry of “phosphate”

Many drug molecules exist naturally in a form called the free base — the raw, active molecule — which is often oily or poorly absorbed. To make it practical, chemists pair the molecule with an acid to form a salt. The salt is more stable, easier to store, and typically dissolves better, which usually means more predictable absorption in the body.

For NSI-189, the chosen partner is phosphoric acid, so the resulting form is NSI-189 phosphate.

The molecular details, for completeness:

• Molecular formula: C₂₂H₃₃N₄O₅P
• Molecular weight: ~464.5 g/mol
• Registry (CAS) numbers: 1270138-40-3 (free base) and 1270138-41-4 (phosphate salt)

Why the salt form

• Stability and shelf life — salt forms resist degradation better than free bases.
• Solubility.
• Dosing arithmetic — this is subtle but important. Part of the total weight of the salt is phosphate, not the active drug. So a “40 mg” dose of the phosphate salt contains slightly less than 40 mg of pure NSI-189. The magnitude of this difference is small (roughly a few percent), but when doses are measured in milligrams, clarity about which form a label refers to matters for accurate comparisons with the published trial data.

It is worth noting that the phosphate salt is the form used in the clinical trials, so “NSI-189 phosphate” is at least consistent with the studied material. That’s a point of scientific continuity — nothing more.

6. Safety and pharmacokinetics: what is known, and the limits of that knowledge

Pharmacokinetics — how the body handles it

From the Phase 1b study, we have real measurements:

• Half-life: approximately 17–20 hours, meaning it clears slowly enough to support once- or twice-daily dosing.
• Steady state (stable blood levels) was reached after about 4–5 days of daily dosing.
• Time to peak concentration: roughly 1–2 hours after an oral dose.
• Exposure increased in a roughly dose-proportional manner across the tested range.
• Metabolism appears to involve oxidative processes with some glucuronide conjugation, and clearance is moderate — approaching liver blood flow.

Safety and tolerability — the reassuring part

• Across both human trials, NSI-189 was well tolerated, and no serious adverse events were reported.
• The most commonly reported side effects were relatively mild: headache and dizziness.
• No seizure activity was observed on monitoring; a quantitative EEG analysis showed subtle changes (increased high-frequency alpha activity) that the authors considered exploratory.

The limits of safety knowledge

• The molecular target is unknown. Without a defined mechanism, it’s harder to predict off-target effects, interactions, or rare long-term consequences. This is a genuine, structural limitation.
• Interactions and special populations are unstudied. There is essentially no solid human data on combining NSI-189 with antidepressants, other psychotropics, stimulants, or alcohol; nor data on pregnancy, adolescents, older adults, or people with bipolar disorder or seizure conditions.

7. A foundational wrinkle: is adult neurogenesis real in humans?

No honest article about NSI-189 can skip this, because the drug’s entire premise rests on a question that remains genuinely unsettled in neuroscience.

For decades, it was accepted that the adult brain generates some new hippocampal neurons. But in 2018, two landmark studies published within weeks of each other reached opposite conclusions:

• Sorrells et al. (Nature) reported that new-neuron production in the human hippocampus drops sharply in childhood and is essentially undetectable in adults.
• Boldrini et al. (Cell Stem Cell) reported lifelong neurogenesis in humans, persisting into old age.

Both were conducted by respected groups using different methods (post-mortem tissue processing, cell markers, and even a clever “birthdating” technique based on carbon-14 from Cold War–era nuclear testing). A lively debate followed (and continues), centered on how reliably certain stain markers identify young neurons and whether human neurogenesis might simply look different from rodent neurogenesis.

Why this matters for NSI-189: the drug was designed to stimulate adult hippocampal neurogenesis. But if the field isn’t even certain how much adult neurogenesis exists in humans — or whether it exists at all in the classic sense — then the therapeutic concept itself sits on shifting ground.

Even proponents of the “sparse or absent human adult neurogenesis” view allow that the hippocampus remains capable of neuroplasticity — rewiring and strengthening existing connections — throughout life. And NSI-189’s demonstrated effects on BDNF and synaptic plasticity (Section 3) could produce benefits through that route, independent of brand-new neurons. So the drug might still have value even if one side of the neurogenesis debate ultimately prevails — but that’s a hypothesis, not a demonstrated fact.

8. Beyond depression: the other conditions studied

One reason NSI-189 commands attention is that “grow and repair the brain” is a versatile idea with applications far beyond mood.

Preclinical (animal) work

• Stroke: In a rat model, NSI-189 improved motor and neurological function, with benefits reportedly maintained for six months after a three-month treatment course, alongside enhanced structural plasticity.
• Radiation-induced cognitive impairment: In rats given brain irradiation (a model for cancer patients who develop cognitive problems after radiotherapy), NSI-189 improved performance on multiple memory tasks, increased neurogenesis, and reduced activated microglia — cells associated with brain inflammation. Notably, the cognitive benefits persisted a month after treatment stopped.
• Angelman syndrome: a rare neurogenetic disorder causing severe cognitive and motor impairment. In a mouse model, NSI-189 enhanced long-term potentiation (a cellular measure of memory formation) and reversed some cognitive and motor deficits, via the TrkB/Akt pathway.

These results are encouraging in the specific ways that animal models can be — but they remain preclinical.